A clinical and cost effectiveness comparison of venlafaxine and selective serotonin reuptake inhibitors (SSRIS) in the management of patients with major depressive disorder from the perspective of an Austrian sickness fund
Journal of medical economics. 7, 93-106
Authors: Howard P, Knight C.
Year: 2004
Category: test1